Shaping the Future of Lateral Flow Assay Development
Faster Lateral Flow Development
We understand that getting results quickly is critical for both you and your customers. We have a wealth of expertise in the development of highly responsive point-of-care lateral flow assays, with over 250 successful projects to date.
Whether you are looking to develop a new point-of-care assay or improve an existing diagnostic test, we offer end-to-end services to deliver robust and reproducible tests ready for the global market.
Using high quality raw materials, we’ll rapidly take your assay from concept to creation, supporting you through development and manufacturing.
Our highly skilled and knowledgeable team has many years of experience developing novel immunoassays that comply with the highest quality and regulatory standards. This lateral flow expertise can be paired with our market-leading gold nanoparticle technology (or your nanoparticle of choice) to deliver the very best outcome for your assay, resulting in a product that will give you a competitive edge.
As part of our full service solution, we have expertise in:
- Sample preparation – including blood separation and experience in using analytes at various concentration
- Antibody/antigen selection
- Detector label selection – including gold, latex, paramagnetic and fluorescent particles
- Numerous conjugation techniques – such as sandwich, competitive and inhibition assays
- Nitrocellulose membrane selection
- Test strip architecture and chemistry
- Reader solutions
Whether you require a complete outsourced service or just an initial feasibility evaluation, we can provide consultation and customised lateral development packages to accommodate most sample matrices, applications and budgets.
Our modular approach means you can select the level of development that suits your needs. For customers looking for a complete ‘turnkey’ assay development, an indicative timeline for a project will take from 12 to 15 months and follows our robust approach:
We’re certified to ISO 13485, and have vast experience of working on lateral flow assay development projects that require FDA approval. A dedicated team of scientists work exclusively on your assay to ensure rapid progress. At the end of the development cycle, we will hand over the design history file, so that you fully own your test.
Morffi signal enhancement technology
Morffi is a signal enhancement technology that improves the sensitivity of lateral flow immunoassays. It can provide up to a 2-fold improvement in the limit of detection, enhances assay sensitivity and may offer a faster time-to-result for situations where a quick diagnosis is critical to patient care.
The Morffi technology overcomes the issues commonly associated with BSA conjugate blocking to improve analyte-specific binding, and is suitable for a wide range of lateral flow applications.
Contact us to see how we can help turn your assay into a market-leading test.